Literature DB >> 12006394

Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study.

E S Tai1, S Demissie, L A Cupples, D Corella, P W Wilson, E J Schaefer, J M Ordovas.   

Abstract

Peroxisome proliferator activated receptor (PPAR) alpha is a member of the nuclear receptor superfamily that regulates key proteins involved in fatty acid oxidation, extracellular lipid metabolism, hemostasis, and inflammation. A L162V polymorphism at the PPARA locus has been associated with alterations in lipid and apolipoprotein concentrations. We studied the association among lipids, lipoproteins, and apolipoproteins and the presence of the L162V polymorphism in 2373 participants (1128 men and 1244 women) in the Framingham Offspring Study. The frequency of the less common allele (V162) was 0.069. The V162 allele was associated with increased serum concentrations of total and LDL cholesterol in men (P=0.0012 and P=0.0004, respectively) and apolipoprotein B in men (P=0.009) and women (P=0.03 after adjustment for age, body mass index, smoking, and use of beta-blockers, diuretics or estrogens). Apolipoprotein (apo) C-III concentrations were higher in carriers of the V162 allele. The association of the L162V polymorphism on LDL cholesterol concentration was greatest in those who also carried the E2 allele at the APOE locus and the G allele at the APOC3 3238C>G polymorphism. This suggests that alterations in triglyceride-rich lipoprotein metabolism may be involved in the generation of the increase in LDL cholesterol observed with the L162V PPARA polymorphism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006394     DOI: 10.1161/01.atv.0000012302.11991.42

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

Review 1.  Genetics, the environment, and lipid abnormalities.

Authors:  Jose M Ordovas; And Haiqing Shen
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

Review 2.  Genetics of the Framingham Heart Study population.

Authors:  Diddahally R Govindaraju; L Adrienne Cupples; William B Kannel; Christopher J O'Donnell; Larry D Atwood; Ralph B D'Agostino; Caroline S Fox; Marty Larson; Daniel Levy; Joanne Murabito; Ramachandran S Vasan; Greta Lee Splansky; Philip A Wolf; Emelia J Benjamin
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

Review 3.  Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Shilu Mathew; Hany Abdel-Hafiz; Abbas Raza; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-08

4.  A genetic risk tool for obesity predisposition assessment and personalized nutrition implementation based on macronutrient intake.

Authors:  Leticia Goni; Marta Cuervo; Fermín I Milagro; J Alfredo Martínez
Journal:  Genes Nutr       Date:  2014-11-28       Impact factor: 5.523

Review 5.  PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure.

Authors:  Neville F Mistry; Sharon Cresci
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

6.  Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes.

Authors:  Sharon Cresci; Philip G Jones; Carmen C Sucharov; Sharon Marsh; David E Lanfear; Adam Garsa; Michael Courtois; Carla J Weinheimer; Jun Wu; Michael A Province; Daniel P Kelly; Howard L McLeod; John A Spertus
Journal:  Pharmacogenomics       Date:  2008-10       Impact factor: 2.533

7.  Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study.

Authors:  Amanda K Golembesky; Marilie D Gammon; Kari E North; Jeannette T Bensen; Jane C Schroeder; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  Carcinogenesis       Date:  2008-06-26       Impact factor: 4.944

8.  Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.

Authors:  Min-Jeong Shin; Alka M Kanaya; Ronald M Krauss
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162

9.  Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke.

Authors:  Daniel A Enquobahrie; Nicholas L Smith; Joshua C Bis; Cara L Carty; Kenneth M Rice; Thomas Lumley; Lucia A Hindorff; Rozenn N Lemaitre; Michelle A Williams; David S Siscovick; Susan R Heckbert; Bruce M Psaty
Journal:  Am J Cardiol       Date:  2008-04-09       Impact factor: 2.778

10.  Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study.

Authors:  Kelly A Volcik; Jennifer A Nettleton; Christie M Ballantyne; Eric Boerwinkle
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.